BNF:

Bacterial infection

Status:

Red

Decision Date:

September 2021

Comments

For adult and children (1 - 17 years of age) with complicated skin/soft tissue infection/right sided endocarditis due to Staphylococcus aureus (microbiologist recommendation only). 

For the treatment of Staphylococcus aureus bacteraemia in adults and children (1-17 years). (Decision Date: February 2018)

Daptomycin has rarely been linked with the development of eosinophilic pneumonia.  The drug should be stopped immediately if this is suspected (cough, fever, dyspnoea).  See MHRA drug safety update Feb 2011.

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again